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ABSTRACT.
Purpose: To compare the cytokine proﬁles of phakic (p) and pseudophakic (ps)
eyes with primary rhegmatogenous retinal detachment (RD) to eyes with
macular holes (MH) and to identify diﬀerences in the speciﬁc cytokine proﬁles.
Methods: Aqueous humour (AH) and vitreous ﬂuid (VF) were obtained from
patients with primary RD without proliferative vitreoretinopathy undergoing
vitrectomy. AH and VF of patients with macular holes (MH) served as controls.
Forty-three diﬀerent cytokines were quantiﬁed using multiplex cytokine analysis.
Intergroup and intragroup comparisons were performed. To control for multiple
comparisons, Holm’s correction was applied.
Results: VF and AH samples of 71 eyes with RD (pRD N = 38; psRD N = 33)
and 26 eyes with MH were included. Cytokine levels in psRD and pRD were
similar (none with >10-fold diﬀerence). The levels of 39 of 43 cytokines in the VF
were signiﬁcantly higher in eyes with RD than in those with MH (>10-fold:
CXLC5, CCL26, CCL1, IL-6, CXCL11, CCL7, CCL13, MIG/CXCL9,
CCL19 and TGF-b1). In the AH, 23 of 43 cytokines were signiﬁcantly higher
compared to MH (>10-fold: CXCL5, IL-4, IL-6, IL-8/CXCL8 and CCL7).
Conclusion: A complex, but nonspeciﬁc cytokine environmental response seems
to initiate immunological and proﬁbrotic processes following RD. Relevant
diﬀerences in the cytokine proﬁles of eyes with pRD and psRD were not
identiﬁed, whereas cytokine diﬀerences between AH and VF in RD could be
explained by upregulation in the vitreous, a higher turn around in the anterior
chamber, or diﬀerences in inﬂammatory cascades in both compartments.
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Introduction
Cytokines are involved in the regula-
tion of inﬂammatory processes,
wound healing and scar formation as
cell-signalling mediators (Zaja-Milato-
vic & Richmond 2008). In eyes with
retinal tears, in particular, those with
retinal detachment (RD), the upregu-
lation of a variety of cytokines has been
shown to mediate a wound-healing
response involving retinal pigment
epithelial (RPE) and glial cells, ﬁbrob-
lasts, and inﬂammatory cells (Hollborn
et al. 2008). This leads to a breakdown
of the uveo vascular barrier, resulting
in an inﬂux of inﬂammatory cells, and
damage to the inner limiting mem-
brane (Hollborn et al. 2008). Conse-
quently, a cascade of migration,
proliferation, and prolonged survival
of involved cells, their production of
extracellular matrix proteins and vit-
real membranes, and ﬁnally the con-
traction of the involved cells is
triggered (Hollborn et al. 2008; Lei
et al. 2010). In such a situation, high
cytokine levels have been found not
only in the vitreous ﬂuid (VF), but also
in the subretinal space (Hollborn et al.
2008). The upregulation of certain
cytokines may also be the stimulus
leading to the development of prolifer-
ative vitreoretinopathy (PVR)
(Roldan-Pallares et al. 2008; Ricker
et al. 2010; Roldan-Pallares et al.
2010). For example, higher vitreal
levels of IL-6, MIF (macrophage inhi-
bitory factor), and the chemokine
ligands CCL2, CCL11, CCL17,
CCL18, CCL19, CCL22, CXCL8,
CXCL9, and CXCL10 have been
reported in eyes with RD and PVR
(Ricker et al. 2010). Cytokine measure-
ments in the anterior chamber and/or
the vitreous have been published for
patients with RD (Ciprian 2015); how-
ever, no conclusive results are available
regarding systematic changes in the
cytokine proﬁle, based on parallel
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investigation of a large number of
cyto- and chemokines, in both the
anterior chamber and in the vitreous
in primary RD without relevant PVR.
This is, however, necessary to estimate
which cytokines are markedly up- and
downregulated in response to RD, and,
also, to better understand if, and how,
the subsequent cascade of proﬁbrotic
and anti-inﬂammatory processes could
be inﬂuenced by targeting speciﬁc
cytokines. Diﬀerences in cytokine
levels have previously been reported
in phakic compared to pseudophakic
eyes for selected cytokines (Jakobsson
et al. 2015).
The aimof this studywas to assess not
only single cytokines, but the proinﬂam-
matory and proﬁbrotic cytokine proﬁles
in the aqueous humour (AH) and VF of
eyes with uncomplicated primary RD,
to determine potential diﬀerences to a
control group of eyes with macular hole
(MH), and to compare phakic and
pseudophakic primary RD.
Patients and Methods
Patients
The investigation was designed as a
prospective study involving a consecu-
tive case series of patients undergoing
pars plana vitrectomy due to primary
RD. Control groups included samples
from otherwise healthy patients under-
going MH surgery (AH and VF sam-
ples), collected in parallel. Patients with
systemic or ocular comorbidities, or
any topical and/or systemic treatments
that may potentially inﬂuence ocular
cytokine levels, were excluded (i.e.
patients with diabetes mellitus, rheuma-
tologic and immunoregulatory diseases,
vitreous haemorrhaging, proliferative
vitreoretinopathy, uveitis, glaucoma,
or any concomitant retinal pathology,
and local or systemic immunomodula-
tory or antiproliferative therapies
including corticosteroids). If both eyes
were aﬀected, only the ﬁrst operated eye
was included. All surgeries were per-
formed at the Berner Augenklinik am
Lindenhofspital, Bern, Switzerland.
The study was approved by the
Ethical commission of the University
of Bern (KEK no. 152/08), was under-
taken with the informed written con-
sent of each of the participants and was
fully compliant with the tenets of the
Declaration of Helsinki.
Handling of VF and AH samples
AH samples were collected by anterior
chamber tap at the beginning of
surgery (200–250 ll), and undiluted
VF samples (approximately 500 ll)
were collected after placement of ports
prior to opening the infusion cannula.
After collection, the samples were
stored at 20° Celsius for up to
2 months, and, thereafter, at 80°
Celsius until the time of the analysis,
which was performed for all samples in
parallel.
Cytokine analyses
The samples were analysed using a
multiplex system (Bio-Plex 100 array
reader with Bio-Plex Manager soft-
ware version 6.1; Bio-Rad, Hercules,
CA, USA). Using this system, multiple
analytes can be detected and quanti-
ﬁed in parallel in a single, small
sample volume. In this study, the
concentrations of 43 cytokines in each
aqueous and vitreous sample
(Table S1) were quantiﬁed. All ana-
lytic procedures were performed
according to the manufacturer’s guide-
lines. In short, magnetic microspheres
tagged with a ﬂuorescent label were
coupled to speciﬁc capture antibodies
and mixed with samples containing
unknown quantities of the cytokines.
Biotinylated detection antibodies and
Streptavidin-R-Phycoerythrin were
then introduced. The mixture was
analysed by ﬂow cytometry. The
instrument’s two lasers identiﬁed
microsphere type and quantiﬁed the
amount of bound antigen. A concen-
tration standard was run in parallel on
each test plate. Measurements were
performed in a blinded manner by a
laboratory technician who was experi-
enced in the execution of this tech-
nique.
Statistical analyses
Data below the working range of
quantiﬁcation of the multiplex assay
were substituted with half of the
lowest level of quantiﬁcation (LLoQ)
provided by the manufacturer which
regularly lay above the internal con-
centration standard run in parallel.
The Shapiro–Wilk test was used to
test whether the data were normally
distributed. Since the criteria for a
normal distribution were not satisﬁed,
the intergroup (pRD versus psRD
versus MH) and intragroup (AH ver-
sus VF) comparisons were conducted
using the nonparametric Mann–Whit-
ney U test and Kruskal–Wallis H test.
A p < 0.05 was considered to be
signiﬁcant. As we made a number of
hypotheses, comparing two or more
groups, for a number of diﬀerent
outcome variables, and since such
multiple comparisons increase the risk
of introducing a Type-I error, we
applied the Holm correction to con-
trol for this type of error, but without
simultaneously, drastically driving up
Type II errors (Holm 1979; Lehmann
& Romano 2005). Cytokine upregula-
tion of >10-fold was deﬁned as poten-
tially clinically relevant. Statistical
evaluation was performed using the
R statistical package (version 3.2.4; R:
A language and environment for sta-
tistical computing, R Foundation for
Statistical Computing, Vienna, Aus-
tria, 2016).
Results
Patients
A total of 71 eyes with primary RD
were included in this study (Fig. 1).
Eyes with any signs of PVR, and any
other potentially confounding ocular or
systemic disease, were excluded. Of the
included eyes, 38 were phakic and 33
eyes pseudophakic. The control group
comprised AH and VF samples of 26
phakic eyes with MH. The mean age
was similar (p > 0.05) between the two
RD groups (pRD: 59.0  14.6 years;
psRD: 66.9  12.0 years) and the con-
trol group (66.7  9.1 years). The
mean time interval between cataract
surgery and vitrectomy in eyes with
psRD was 3.9  3.8 years (range 0.1–
14.2 years), three of them had under-
gone cataract surgery within 6 months
before the development of RD. The
duration of symptoms (pRD
7.0  6.5 days; psRD 9.9  14.5 days;
p = 0.83), the number of retinal breaks
(pRD 1.5  1.1; psRD 1.5  0.9;
p = 0.69), the portion of patients with
retinal breaks with a diameter of more
than one clock hour (pRD 33.3%;
psRD 21.9%; p = 0.53) and the loca-
tion of the retinal breaks (superior:
pRD 64.9%; psRD 71.0%; p = 0.90)
were similar between the groups. The
postoperative outcome was similar
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regarding redetachment rate (pRD
10.5% versus psRD 15.1%, p = 0.83)
and PVR development (pRD versus
psRD: PVR-grade ≤B: 2 versus 0
patients; PVR-grade C1 and C2: 2
versus 2 patients; PVR-grade ≥C3: 0
versus 3 patients; p = 0.22). The mea-
sured cytokine levels in the VF and AH
of all groups are shown in Figs 2
(heatmap), 3A, B (cytokine proﬁles
displayed as curves to depict the cyto-
kine environment).
Comparisons of cytokine profiles between
RD and MH
A total of 39 of the tested 43 cytokines
were signiﬁcantly higher in the vitreous
of the RD group compared to the MH
group (Table 1).Out of these, a≥10-fold
upregulation in the RD group was
observed for CXLC5, CCL26, CCL1,
IL-6, CXCL11, CCL7, CCL13, MIG/
CXCL9,CCL19andTGF-b1 (Fig. 4A).
On the other hand, there were no diﬀer-
ences in the levels of CCL27, CXCL16,
CCL17andTGF–b2between the eyesof
subjects with RD andMH.
Signiﬁcantly higher levels were
reported for 23 cytokines in the AH
of the eyes of subjects with RD
compared to those with MH (with a
≥10-fold upregulation in CXCL5, IL-
4, IL-6, IL-8/CXCL8 and CCL7;
Table 2, Fig. 4B), whereas signiﬁ-
cantly lower levels were reported for
GM-CSF and TGF-b2 (diﬀerence
<10-fold, each).
Intragroup comparison of VF and AH
In patients with RD, the cytokines IL-
16 and CCL7 were signiﬁcantly higher
in the VF than in the AH, whereas
CCL24, GM-CSF, TGF-b1 and TGF-
b2 and TGF-b3 were signiﬁcantly lower
in the VF. However, none of these
diﬀerences was found to be ≥10-fold.
In eyes with MH, in comparison, a
signiﬁcant diﬀerence in the levels of
most cytokines was found between the
VF and the AH (i.e. in the AH, signif-
icantly higher levels of CCL21, CXCL5,
CCL11, CCL24, CCL26, CX3CL1,
GM-CSF, CXCL1, CCL1, IL-1b, IL-6,
IL-8/CXCL8, IL-10, IL-16, CXCL11,
CCL8, CCL13, MIF, MIG/CXCL9,
CCL3, CCL25, TNF-a, TGF-b1 and
TGF-b2 were found, thereof CXCL5,
CCL1, CXCL11, CCL13 and TGF-b1
were>10-fold higher than in theVF).On
the other hand, CXCL16 was lower in
the AH compared to the VF in eyes with
MH (Fig. 2).
Comparisons of cytokine profiles in RD:
pseudophakic versus phakic eyes
Similar cytokine proﬁles were observed
in the VF of phakic and pseudophakic
eyes, with slightly, but not signiﬁcantly,
higher cytokine levels in the pseu-
dophakic RD group for the majority
of cytokines (Table S2, Figs 2 and 3A).
Only IL-6 was signiﬁcantly higher
(6.7-fold) in the pseudophakic RD
group. On the other hand, the levels
of GM-CSF, CCL3, and TGF-b2 were
Fig. 1. Cytokine levels in the vitreous and aqueous humour of phakic (N = 38) and pseudophakic
(N = 33) eyes of patients with primary retinal detachment (N = 71) were compared to eyes with
macular holes (N = 26).
Fig. 2. Heatmaps for all cytokines measured in the aqueous humour and vitreous of eyes with
phakic (pRD) and pseudophakic (psRD) retinal detachment and macular holes.
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slightly, but not signiﬁcantly, lower in
the pseudophakic RD group.
Similarly, in the AH of both groups,
slightly, but not signiﬁcantly, higher
cytokine levels were observed in the
pseudophakic RD group for 41 cytoki-
nes (Table S3, Fig. 3B). The levels of
only two cytokines (CXCL6 and
CCL20) were signiﬁcantly higher in
the pseudophakic RD group and that
of only one cytokine (TGF-b2) was
slightly, but not signiﬁcantly, lower;
however, none of them showed a more
than 10-fold diﬀerence.
Discussion
The ﬁnding that 39 of the 43 tested
cytokines in our study were signiﬁ-
cantly diﬀerent between the RD group
and the control group indicates a broad
and nonspeciﬁc environmental change
and strongly argues against drawing
conclusions from diﬀerences in single
cytokines. A signiﬁcant upregulation
had been reported for the majority of
these cytokines (Abu el-Asrar et al.
1992; de Boer et al. 1993; Elner et al.
1995; Banerjee et al. 2007; Yoshimura
et al. 2009). Beyond application of the
Holm correction, we therefore intro-
duced the ‘upregulation factor’ as a
marker of biological relevance beyond
signiﬁcant cytokine diﬀerences. A 10-
fold upregulation in the vitreous was
still present in more than 23% (10 of
43) of the tested cytokines. Our 10-fold
cut-oﬀ level was a cautious assumption
(in comparison with the calculation of
statistical signiﬁcance), also consider-
ing the high variance of measurements.
From systemic and ocular inﬂamma-
tory disease it is known that two- to
threefold diﬀerences in TNFa levels are
found between healthy and diseased
and even lower diﬀerences are linked to
relevant clinical diﬀerences in the dis-
ease activity (Mesquida et al. 2014;
Chen et al. 2015; Lopalco et al. 2017).
We think that our multiplex
approach allowed us to identify the
most abundant cytokines in a complex
cytokine environmental change, sug-
gesting their potential biological role
in the evolution of RD, thus making
them deserve of closer attention. The
role of immune mediators in RD has
also been studied in animal models (Jo
et al. 2003; Nakazawa et al. 2007, 2011;
Yang et al. 2007; Chong et al. 2008).
Whereas in the majority of those pub-
lications, an arbitrary selection of few
cytokines was analysed, we intended to
reveal a whole environmental cytokine
change by analysing a broad set of
cytokines previously reported as abun-
dant. Moreover, we based our analysis
on maximally possible homogenous
groups of patients after exclusion not
only of ocular, but also systemic,
comorbidities and their treatments
(Zandi et al. 2016). In this study, we
also aimed to evaluate a potential
inﬂuence of the lens status on the
cytokine milieu in eyes with RD, but
failed to detect relevant diﬀerences in
the biologic milieu between phakic and
pseudophakic states. This is in line with
recent publications, where other clinical
factors (e.g. number, size and location
of retinal breaks, and presence of PVR)
and not primarily the lens status had a
relevant inﬂuence on the clinical out-
come (Lumi et al. 2016; Takkar et al.
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Fig. 3. (A) Proﬁle (curves) of vitreal cytokine levels in eyes with phakic (pRD) and pseudophakic
(psRD) retinal detachment and macular holes (MH) to illustrate the cytokine environment. (B)
Proﬁle (curves) of aqueous humour (AH) cytokine levels in eyes with pRD and psRD retinal
detachment and MH to illustrate the cytokine environment.
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2016; Xu et al. 2018). No relevant
clinical diﬀerences in the reattachment
rates between eyes with phakic and
pseudophakic RD have been reported
by (Christensen & Villumsen 2005). In
our study, clinical characteristics of RD
and also postoperative outcome were
similar between the pRD and psRD
group, which might explain the similar-
ity of the cytokine proﬁles.
The RD-evoked changes may thus
represent an undirected, acute response
to tissue trauma, which cannot readily
be attributed to one single biological
activation factor for ﬁbroblasts or
inﬂammatory cells (Asaria & Charteris
2006; Garweg et al. 2013). Such non-
speciﬁc upregulation is observed in a
variety of tissues and organs during
wound-healing processes (Pastor et al.
2002; Ricker et al. 2010). However, in
the eye, this response may have disas-
trous consequences on the maintenance
of visual function due to the develop-
ment of PVR and tractional redetach-
ment after primarily successful
reattachment surgery. Cytokine con-
centrations in the blood in ten of our
patients were about 500-times higher
than in the vitreous of eyes with retinal
detachment (data not shown). This is
well in the range of our and published
experience from other ﬁelds, namely
antibody investigations in uveitis (Gar-
weg et al. 2005). Clearly, any minimal
impact onto the uveovascular barrier
would be expected to have a major
impact on cytokine concentrations.
The high variability in cytokine levels
between eyes with RD (even after
excluding eyes with intravitreal bleed-
ing) thus probably indicates a wide
Table 1. Cytokine levels (pg/ml; mean) in the vitreous (VF) of eyes with retinal detachment (RD) versus macular holes (MH) revealed a signiﬁcant
upregulation of 39 out of 43 cytokines.
Cytokines
VF RD VF MH
p value Holm correctionMean SD Mean SD
CCL21 2112.1 4277.9 341.3 190.5 8.75E-08 Sig.
CXCL13 2.0 3.2 0.4 0.2 2.28E-08 Sig.
CCL27 7.5 24.3 2.4 1.9 0.04051 n.s.
CXCL5 165.1 203.0 12.3 7.2 1.91E-08 Sig.
CCL11 12.9 15.9 1.4 1.2 9.46E-11 Sig.
CCL24 19.8 20.8 6.5 6.6 7.33E-07 Sig.
CCL26 9.1 13.1 0.5 0.3 1.38E-10 Sig.
CX3CL1 60.4 56.9 22.1 14.4 5.94E-05 Sig.
CXCL6 2.4 4.0 0.4 0.0 6.00E-05 Sig.
GM-CSF 44.5 18.6 30.0 12.7 0.000713 Sig.
CXCL1 65.5 66.8 7.2 9.8 5.46E-11 Sig.
CXCL2 24.0 50.4 4.9 2.2 0.0003174 Sig.
CCL1 34.7 59.0 0.9 0.0 2.14E-10 Sig.
IFN-c 8.8 12.2 1.2 0.0 3.21E-06 Sig.
IL-1b 1.4 1.9 0.3 0.2 4.21E-08 Sig.
IL-2 1.5 1.8 0.4 0.0 7.84E-07 Sig.
IL-4 3.0 4.8 0.8 0.5 0.004736 Sig.
IL-6 121.9 343.5 9.5 20.2 4.35E-10 Sig.
IL-8/CXCL8 37.0 52.9 9.4 4.8 9.71E-10 Sig.
IL-10 7.2 5.7 1.1 1.1 5.22E-10 Sig.
IL-16 56.4 45.7 9.8 19.5 1.07E-09 Sig.
CXCL10 381.8 1631.4 52.9 31.0 2.53E-07 Sig.
CXCL11 4.9 8.0 0.2 0.1 2.04E-10 Sig.
CCL2 1469.4 1270.9 792.7 591.6 6.36E-09 Sig.
CCL8 13.0 32.5 1.7 1.2 2.09E-10 Sig.
CCL7 21.7 24.6 1.0 0.0 6.92E-10 Sig.
CCL13 2.2 2.4 0.2 0.0 5.69E-10 Sig.
CCL22 12.9 12.9 3.6 3.3 3.74E-06 Sig.
MIF 98575.4 90280.5 27059.8 37164.6 9.58E-08 Sig.
MIG/CXCL9 327.0 2405.0 11.0 11.1 1.65E-08 Sig.
CCL3 3.8 8.0 0.6 0.3 5.47E-11 Sig.
CCL15 777.0 799.7 419.2 413.7 0.0006062 Sig.
CCL20 10.2 13.3 4.1 3.4 0.0005531 Sig.
CCL19 40.3 65.9 2.7 2.0 4.44E-10 Sig.
CCL23 16.5 19.1 7.3 7.3 0.0005097 Sig.
CXCL16 808.8 301.1 659.8 239.5 0.03421 n.s.
CXCL12 163.6 158.3 48.9 30.7 1.95E-07 Sig.
CCL17 5.9 19.6 0.9 0.0 0.03315 n.s.
CCL25 368.8 421.9 45.9 43.2 5.02E-10 Sig.
TNF-a 13.7 18.9 3.4 2.2 8.42E-09 Sig.
TGF-b1 100.4 220.7 9.3 32.1 0.00202 Sig.
TGF-b2 1257.7 874.2 998.0 529.8 0.388 n.s.
TGF-b3 10.5 21.8 2.2 3.4 0.003675 Sig.
n.s. = not signiﬁcant after application of the Holm correction; Sig. = signiﬁcant (p < 0.0016).
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range in the dimension of trauma to the
blood–retinal barrier most likely asso-
ciated with the number and size of
retinal breaks, the acuity and extension
of the retinal detachment as well as its
duration. Further studies with higher
sample numbers would be necessary to
evaluate an impact of these parameters
after correction for any underlying
local and systemic comorbidity and
their corresponding therapies. More
importantly, this would not bear any
therapeutic consequences since none of
these factors adding to the severity of
uveovascular barrier disruption can be
inﬂuenced except by the surgery itself.
That, on the other hand, single cytoki-
nes were speciﬁcally upregulated can-
not be traced to the breakdown of the
uveovascular barrier, but advocates a
tissue-speciﬁc response.
Interestingly, adjuvant treatments
with intraocular or systemic corticos-
teroids during vitreoretinal surgery for
RD have broadly been used, though
they have not been found to correlate
with improvement of the clinical out-
come (Koerner et al. 1982; Weller et al.
1990; Berger et al. 1996; Cheema et al.
2007). Therefore, a complete, and
nonspeciﬁc, dampening of cytokine
upregulation may not be the ideal
approach. A more targeted therapeutic
approach, applied as early as possible,
might possibly slow down this process
at a stage before loss of retinal stability
and further functional loss have
occurred; however, little data regarding
potential targets are available. Ranibi-
zumab, for example, has been shown to
reduce the bioactivity of vitreous from
patients and experimental animals with
PVR, and protected rabbits from
developing PVR (Pennock et al.
2013). A strategy to identify cytokines
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Fig. 4. (A) Cytokines with signiﬁcant and relevant (>10-fold) upregulation in the vitreous of eyes with retinal detachment (RD) versus macular holes
(MH). (B) Cytokines with signiﬁcant and relevant (>10-fold) upregulation in the aqueous humour of eyes with RD versus MH.
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with a biological role, indicated by
relevant changes in their concentration,
may not be as simple to identify
promising targets for anti-inﬂamma-
tory or antiﬁbrotic treatment. Whether
our strategy of assessing a broad
cytokine environment and identifying
the most abundant of these factors is
able to deliver these promising targets
will be addressed subsequently.
Cytokine levels in eyes with psRD
and pRD in our study were quite
similar in the vitreous as well as in
the AH, as was the severity and
duration of retinal detachment. In a
previous study by (Jakobsson et al.
2015), a total of 14 cytokines (eotaxin,
IP-10, MCP-1, MDC, MIP-1a, MIP-
1b, TARC, IL-12p40, IL-15, IL-16, IL-
7, VEGF, IL-6, IL-8) were found to be
signiﬁcantly upregulated in pseudopha-
kic compared to phakic eyes of patients
with MH, epiretinal membranes, vitre-
ous macular traction, or vitreous ﬂoa-
ters, but corresponding data pertaining
to RD have not been available. IL-6,
IL-8, IL-15 and IL-16 revealed a sig-
niﬁcant trend of decreasing
concentration over time (Jakobsson
et al. 2015). Based on the absolute
cytokine concentrations reported by
Jakobsson et al., it has to be assumed
that in the presence of RD – as in our
study – the manifold greater upregula-
tion of cytokines outweighs potential
diﬀerences between pseudophakic and
phakic state. This hypothesis is
strengthened by our ﬁndings that more
than 90% of cytokines were upregu-
lated in patients with RD compared to
MH. Moreover, higher IL-6 levels in
pseudophakic eyes have not only been
Table 2. Cytokine levels (pg/ml; mean) in the aqueous humour (AH) of eyes with retinal detachment (RD) versus macular holes (MH) revealed a
signiﬁcant upregulation of 23 out of 43 cytokines.
Cytokines
AH RD AH MH
p value Holm correctionMean SD Mean SD
CCL21 1313.1 1327.1 714.5 380.6 0.01628 n.s.
CXCL13 4.5 4.7 0.5 0.6 2.229e-08 Sig.
CCL27 3.3 6.5 1.4 2.9 0.06004 n.s.
CXCL5 2384.9 10941.8 178.2 143.3 0.06488 n.s.
CCL11 9.7 11.7 5.1 2.7 0.01211 n.s.
CCL24 44.3 136.7 26.9 14.8 0.7323 n.s.
CCL26 7.3 7.9 3.5 3.1 0.00168 Sig.
CX3CL1 82.2 120.9 43.4 19.0 0.04425 n.s.
CXCL6 2.6 5.1 0.7 0.8 0.002821 n.s.
GM-CSF 91.7 56.4 152.0 101.5 2.37E-07 Sig.
CXCL1 107.6 206.3 38.7 26.2 5.63E-05 Sig.
CXCL2 18.1 36.3 4.1 3.1 0.06299 n.s.
CCL1 15.4 16.3 11.4 9.3 0.1388 n.s.
IFN-c 12.2 22.8 1.6 1.5 5.69E-06 Sig.
IL-1b 2.9 6.1 1.0 0.8 0.05999 n.s.
IL-2 1.7 2.1 0.6 0.6 2.04E-05 Sig.
IL-4 13.1 51.1 0.8 0.8 0.04502 n.s.
IL-6 822.9 3764.6 27.5 97.9 2.76E-07 Sig.
IL-8/CXCL8 51.8 108.5 5.0 6.6 5.43E-10 Sig.
IL-10 8.7 10.4 3.3 3.1 1.933e-05 Sig.
IL-16 25.5 29.9 14.1 11.6 0.02427 n.s.
CXCL10 350.3 1512.2 41.3 35.2 3.73E-06 Sig.
CXCL11 1.9 2.3 0.9 0.9 0.001688 Sig.
CCL2 1592.1 2431.5 415.9 231.1 1.58E-08 Sig.
CCL8 10.9 15.9 2.8 1.9 2.79E-05 Sig.
CCL7 12.0 19.8 1.1 1.0 7.423e-05 Sig.
CCL13 3.3 6.9 1.3 0.6 0.03057 n.s.
CCL22 20.8 26.6 6.8 5.6 1.51E-05 Sig.
MIF 77741.9 66286.8 37135.4 20113.5 0.0006832 Sig.
MIG/CXCL9 68.0 324.3 15.0 19.3 0.06706 n.s.
CCL3 2.1 1.8 0.9 0.5 9.01E-05 Sig.
CCL15 812.4 898.4 520.1 564.6 0.04013 n.s.
CCL20 17.2 43.2 3.3 3.3 1.21E-06 Sig.
CCL19 21.2 27.0 4.1 4.2 2.70E-05 Sig.
CCL23 24.5 35.8 11.7 11.4 0.02369 n.s.
CXCL16 829.4 894.5 446.1 189.4 0.0001381 Sig.
CXCL12 223.8 334.9 94.5 70.7 0.003502 n.s.
CCL17 4.2 11.0 1.1 0.9 0.2377 n.s.
CCL25 164.3 142.9 105.9 67.5 0.06687 n.s.
TNF-a 11.5 13.1 5.6 4.7 0.000754 Sig.
TGF-b1 388.3 456.9 182.0 149.9 0.06905 n.s.
TGF-b2 2454.2 1565.7 3496.0 1427.5 0.001195 Sig.
TGF-b3 30.0 45.6 4.2 9.7 4.98E-06 Sig.
n.s. = not signiﬁcant after application of the Holm correction; Sig. = signiﬁcant (p < 0.0016).
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found in our study, but have also been
reported in pseudophakic versus pha-
kic eyes of patients with vitreoretinal
pathologies, excluding RD (Jakobsson
et al. 2015).
Though the source of this cytokine
production has not yet been identiﬁed,
the similarity between the cytokine
proﬁles in the AH and VF in eyes with
RD ﬁts well with a washout of cytoki-
nes from the posterior to the anterior
segment. The diﬀerences between the
AH and VF for single cytokines may
result from a gradient from the retina
to the vitreous, from the higher turn
around in the anterior chamber, or
from diﬀerences in the inﬂammatory
cascade induced in both compartments
in response to RD. The similarity
between cytokine levels in eyes with
phakic and pseudophakic RD reveals
that the presence of an intraocular lens
(IOL) does not change the amount of
this washout and, furthermore, that
diﬀerences in clinical outcomes and
PVR incidence may not be attributed
to lens-state-related biological diﬀer-
ences, which in turn advocates for the
assumed role of diﬀerences in mechan-
ical forces.
Our ﬁnding of upregulation of proﬁ-
brotic and proinﬂammatory cytokines
in 39 out of 43 cytokines in eyeswithRD
compared to MH is consistent with
results of previous studies, which
showed such changes for IL-6 and IL-8
(Yoshimura et al. 2009; Takahashi
et al. 2016); MCP1, MIP-1b and IP10
(Takahashi et al. 2016); and, inRDwith
PVR, for IL-6, CXCL8/IL-8, CCL2,
and, in some samples, also for IL-10,
TNF-a, TNF-c, CCL3, CCL4, CCL5,
G-CSF and FGF (Kauﬀmann et al.
1994; Banerjee et al. 2007; Rasier et al.
2010). Our study conﬁrms the outstand-
ing >10-fold upregulation of IL-6 in the
vitreous of RD eyes compared to eyes
with MH, but reveals also the upregu-
lation of CXLC5, CCL26, CCL1,
CXCL11, CCL7, CCL13, MIG/
CXCL9,CCL19 andTGF-b1 (>10-fold,
each) compared to eyes with MH.
Interestingly, any of the here identiﬁed,
most abundant cytokines have been
identiﬁed as key players in the inﬂam-
matory response (Shinkai et al. 1999;
Chen et al. 2004; Radeke et al. 2007;
Hooks et al. 2008; Turner et al. 2014;
Wermuth & Jimenez 2015). IL-6 is a
proinﬂammatory cytokine that ampli-
ﬁes inﬂammatory responses and is
involved in wound-healing and
leucocyte recruitment (Romano et al.
1997; Wu et al. 2010). Elevated IL-6
levels have been found in RD and other
vitreoretinal diseases, such as diabetic
retinopathy and retinal vein occlusion
(Yoshimura et al. 2009). Increased
levels of IL-6 have also been reported
in PVR (El-Ghrably et al. 2001), with
invading cells being postulated as their
source. Human RPE cells increase
CXCL11 production in an inﬂamma-
tory milieu, presumably contributing to
the inﬂammation and angiogenesis in
the retina, retinal pigment epithelium
and choroid complex (Shi et al. 2008;
Juel et al. 2012). This is consistent with
our hypothesis that these cytokines with
>10-times upregulation are potentially
suitable as targets for PVR prophylaxis
and treatment.
The strengths of this study are its
strict selection criteria, resulting in
homogenous cohorts, and a relatively
large sample size with the possibility of
subgroup analysis (e.g. phakic versus
pseudophakic RD). The use of a multi-
plex device allowed analysis of a large
set of cytokines, in parallel, and after
conﬁrming these results by repeated
measurements in a subset of samples,
with a high sensitivity and repro-
ducibility for measurements of cyto-
kine concentrations in the picogram
range. Unfortunately, but understand-
ably, no VF for healthy eyes could be
harvested due to ethical reasons. All
samples were harvested in the same
fashion (see methods section).
Although storage conditions and times
might theoretically have an impact on
absolute cytokine concentrations, we
assume that this would have aﬀected all
groups in the same way. No relevant
interference with intergroup compar-
isons of such a potential bias is
expected, especially none explaining
the >10-fold diﬀerences that we have
observed. Based on an average interval
of 3.8 years between cataract surgery
and retinal detachment, we are not able
to address a potential timely associa-
tion between recent cataract surgery,
the development of RD and cytokine
concentrations.
In conclusion, our results show that
the majority of single cytokines are
signiﬁcantly upregulated indicating
substantial changes in the proinﬂam-
matory and proﬁbrotic cytokine envi-
ronment early in RD. We strongly
believe that the correction for multi-
ple comparisons and identiﬁcation of
cytokines with an at least 10-fold
upregulation allows to more speciﬁ-
cally identify only the biologically
relevant changes. That single cytoki-
nes were speciﬁcally more abundant
than the majority might indicate a
local response which could speciﬁcally
be targeted. Lens status does not
seem to play a relevant role in this
process.
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